New Novus (300765.SZ) plans to issue additional cash and pay cash to purchase 100% of Shijiao Baig's shares to extend the industrial layout transaction at a price of 7.6 billion yuan

According to the Zhitong Finance App, Xinnovo (300765.SZ) released a report on issuing shares and paying cash to purchase assets and raising supporting capital and related transactions (draft). The listed company plans to purchase 100% of the shares of Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd. (Shiyao Baig) Co., Ltd. (Shiyao Baig for short) by issuing shares and paying cash in cash. Among them, the proportion of consideration paid by issuing shares and cash accounted for 90% and 10% of the transaction consideration, respectively. The share consideration amount was 6.84 billion yuan, and the consideration amount paid in cash was 760 million yuan. After the transaction is completed, the listed company will hold 100% of the shares of Shiyao 100g.

According to reports, Shiyao Baike, the target company that issued shares and paid cash to purchase assets, is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It mainly focuses on cutting-edge fields of innovative biopharmaceuticals such as long-acting protein drugs, and has strong R&D, industrialization, and commercialization capabilities. Through this transaction, the listed company will further extend the biomedical layout to cutting-edge fields such as long-term protein, which is conducive to deepening the company's technology and product layout, upgrading the product structure and layout of innovative biopharmaceutical pipelines, accelerating the construction of a leading innovative biomedical platform, and continuously improving the company's overall value and comprehensive competitive strength.